DUALITYBIO-B

9606
97.3004.79% ( -4.900 )
Delay Closed: Nov 16, 16:08:11

Overview

DUALITYBIO-B (9606)

Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, au...

Open
101.000
High
102.200
Low
95.750
Prev. Close
102.200
Volume
684.93K
Turnover
66.76M
Avg Price
97.477
Bid/Ask Ratio
-30.00%
Amplitude
6.31%
52wk High
376.800
Volume Ratio
0.48
Turnover Ratio
0.75%
52wk Low
95.750
HK Mkt Cap
8.86B
Market CapHKD
8.86B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-18.19
EPSDynamic
-23.21
EPSStatic
--
BVPS
18.35
P/B
5.30
HK Shares
91.05M
Dividend YieldTTM
--
DividendTTM
--
Shares
91.05M
Min lot size
100
Currency
HKD

DUALITYBIO-B Analyst Rating

View more

Forecast & Rating

Oct 27, 2026
Price forecast
HK$395.78306.76%
Forecast & RatingStrong buy
8analysts
  • Strong buy75.00%
  • Buy25.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    DualityBio fell 4.79% to HK$97.30 as the DYNASTY-Breast02 Phase III readout showed trastuzumab pamirtecan delivering limited benefit in HR+/HER2-low breast cancer, with peer MediLink's similarly modest breast cancer data adding pressure; shares rebounded to HK$99.15 in the morning before sliding to HK$95.75, a fresh 52-week low, in the afternoon. Operating figures remain strained: Q2 2026 revenue of HK$126.7 million was down 81.19% year on year, while the net loss of HK$529.9 million narrowed 53.36% and EPS came in at -HK$5.87, leaving PE at -5.35 and PB at 5.30. The stock is down 67.17% year to date and 74.18% below its January 12 high of HK$376.80, well under the MA20 of HK$118.72 and MA60 of HK$164.93. Though chairman Zhu Zhongyuan plans to double his share purchases to as much as US$10 million, and the company repurchased 158,000 shares for over HK$17 million this week.

  2. Nov, 13

    DualityBio (9606.HK) fell about 6% to HKD102.20, opening high and closing near the day's low as the limited benefit shown in the Phase III DYNASTY-Breast02 trial of trastuzumab pamirtecan in HR+/HER2-low breast cancer extended the selling pressure since late October. The stock traded down from an intraday HKD107.50 to HKD101.30. Q2 revenue was HKD126.7 million, down 81.19% year on year, while the net loss of HKD529.9 million narrowed 53.36% year on year. The net loss came with EPS of -HKD5.8717 and an operating loss of HKD529.8 million, a 932.37% year-on-year deterioration. At HKD102.20, the shares are only 6.46% above the 52-week low of HKD96, down 65.52% year to date, and below the 20-day moving average of HKD122.35 and the 60-day average of HKD166.44; they also sit 72.88% below the January 12 high of HKD376.80. Partly offsetting this, the company bought back 158,000 shares on Wednesday for more than HKD17 million, and Chairman Zhu Zhongyuan plans to double his share purchases to as much as USD10 million.

  3. Nov, 10

    DualityBio-B (9606.HK) closed at HK$107.20, up 2.88% from HK$104.20, in a spike-fade-recover session: it touched HK$110.00 at 09:39 BJ before sliding to HK$104.70 at 11:11 BJ, on 612,800 shares. The rebound was anchored by insider buying, with chairman Zhu Zhongyuan repeatedly adding 10,000-30,000 shares at HK$103.42-108.75, while the company repurchased about 102,000 shares for roughly HK$5.86 million in the Nov 2-6 window and directors and senior management pledged a six-month lock-up. Fundamentals remain the counterweight: Q2 2026 revenue fell 81.19% year on year to HK$126.7 million and the HK$529.9 million net loss narrowed 53.36% but stayed in the red. The stock is down 63.83% year to date, 71.55% below its 52-week high of HK$376.80 and only 11.67% above the Nov 1 low of HK$96.00, well under its MA20 of HK$130.97. Though turnover of just 0.67% means thin volume magnified the intraday swings.

  4. Nov, 6

    DualityBio fell 5.7% to HK$104.9, reversing an early rise to HK$108.8 in the morning session and sliding to HK$103.1 in the afternoon, as a roughly 2% pullback in the Hong Kong biotech complex, with GenScript Bio down 12%, outweighed company-level support. Turnover was HK$77.7 million. The company repurchased 25,000 shares on 5 November, chairman Zhu Zhongyuan added 30,000 shares at HK$103.423, and directors and senior management pledged a six-month lock-up, while CMBI maintained a Buy rating after Elfe-D combination data. Fundamentals remain weak: Q2 2026 revenue of HK$126.7 million was down 81.2% year on year, with a net loss of HK$529.9 million and loss per share of HK$5.87. The stock is down 64.6% year to date and 72.2% below its 52-week high of HK$376.8, trading under both the MA20 of HK$138.5 and MA60 of HK$173.2. Repeated buybacks and the lock-up pledge offer only a partial cushion, though.

  5. Nov, 4

    DualityBio reversed early weakness to close up 7.6% at HK$109.10, having slipped to HK$100.60 in the morning session before rallying to HK$109.70 in the afternoon. Chairman Zhu Zhongyuan bought 30,000 shares at HK$103.423, the company repurchased 68,500 shares for roughly HK$7.15 million across three sessions since October 30, directors and senior management committed to a six-month voluntary lock-up and plan to add up to US$5 million, and CMBI rated the stock Buy on Elfe-D combination data supporting the ADC+IO 2.0 thesis, while the biotech index rose nearly 8% in the afternoon. Though Q2 2026 revenue fell 81.19% year on year to HK$126.7 million alongside a HK$529.9 million net loss, and the price sits below MA20 of HK$146.87 and MA60 of HK$176.13, down 63.19% year to date, 71.05% under its 52-week high of HK$376.80 and only 13.65% above the HK$96.00 low of November 1.

News

Bullish vs. Bearish — Last 3 Months

4.4k followers · 0 opinions
▲Bullish50%
50%Bearish▼